stoxline Quote Chart Rank Option Currency Glossary
Marinus Pharmaceuticals, Inc. (MRNS)
8.5  0.03 (0.35%)    12-08 16:00
Open: 8.44
High: 8.75
Volume: 300,631
Pre. Close: 8.47
Low: 8.28
Market Cap: 464(M)
Technical analysis
2023-12-08 4:44:49 PM
Short term     
Mid term     
Targets 6-month :  10.22 1-year :  11.93
Resists First :  8.75 Second :  10.22
Pivot price 6.99
Supports First :  6.78 Second :  5.57
MAs MA(5) :  8.13 MA(20) :  6.79
MA(100) :  7.4 MA(250) :  7.34
MACD MACD :  0.4 Signal :  0.1
%K %D K(14,3) :  94.1 D(3) :  94.7
RSI RSI(14): 72.5
52-week High :  11.14 Low :  3.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MRNS ] has closed below upper band by 7.8%. Bollinger Bands are 69.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.76 - 8.78 8.78 - 8.81
Low: 8.2 - 8.23 8.23 - 8.27
Close: 8.45 - 8.49 8.49 - 8.54
Company Description

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Headline News

Thu, 07 Dec 2023
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Mon, 20 Nov 2023
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results ... - Business Wire

Tue, 14 Nov 2023
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference - Business Wire

Wed, 08 Nov 2023
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript - Yahoo Finance

Tue, 07 Nov 2023
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Quartz

Tue, 07 Nov 2023
Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 55 (M)
Shares Float 43 (M)
Held by Insiders 0.7 (%)
Held by Institutions 86.4 (%)
Shares Short 4,550 (K)
Shares Short P.Month 3,850 (K)
Stock Financials
EPS -2.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin 0 %
Operating Margin -431.3 %
Return on Assets (ttm) -40.6 %
Return on Equity (ttm) -196.2 %
Qtrly Rev. Growth 213.6 %
Gross Profit (p.s.) -1.03
Sales Per Share 0.56
EBITDA (p.s.) -2.19
Qtrly Earnings Growth 0 %
Operating Cash Flow -113 (M)
Levered Free Cash Flow -75 (M)
Stock Valuations
PE Ratio -3.06
PEG Ratio -0.2
Price to Book value 8.5
Price to Sales 14.98
Price to Cash Flow -4.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android